{
    "balance": {
        "data": [
            "Consolidated Balance Sheets at March 31, 2020 and December 31, 2019 (unaudited)\t2\tCondensed Consolidated Statements of Income for the Three Months Ended March 31, 2020 and 2019 (unaudited)\t3\tCondensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2020 and 2019 (unaudited)\t4\tCondensed Consolidated Statements of Stockholders  Equity for the Three Months Ended March 31, 2020 and 2019 (unaudited)\t5\tCondensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019 (unaudited)\t6\tNotes to Condensed Consolidated Financial Statements (unaudited)\t7\tItem 2.\tManagement s Discussion and Analysis of Financial Condition and Results of Operations\t24\tItem 3.\tQuantitative and Qualitative Disclosures About Market Risk\t33\tItem 4.\tControls and Procedures\t33\tPART II.\tOTHER INFORMATION\t34\tItem 1.\tLegal Proceedings\t34\tItem 1A.\tRisk Factors\t34\tItem 2.\tUnregistered Sales of Equity Securities and Use of Proceeds\t48\tItem 3.\tDefaults Upon Senior Securities\t48\tItem 4.\tMine Safety Disclosures\t48\tItem 5.\tOther Information\t48\tItem 6.\tExhibits\t48\tSIGNATURES\t52\tWe own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD\t\u00ae\t, GILEAD SCIENCES\t\u00ae\t, AMBISOME\t\u00ae\t, ATRIPLA\t\u00ae\t, BIKTARVY\t\u00ae\t, CAYSTON\t\u00ae\t, COMPLERA\t\u00ae\t, DESCOVY\t\u00ae\t, DESCOVY FOR PREP\t\u00ae\t,\tEMTRIVA\t\u00ae\t, EPCLUSA\t\u00ae\t, EVIPLERA\t\u00ae\t, GENVOYA\t\u00ae\t, HARVONI\t\u00ae\t, HEPSERA\t\u00ae\t, LETAIRIS\t\u00ae\t, ODEFSEY\t\u00ae\t, RANEXA\t\u00ae\t, SOVALDI\t\u00ae\t, STRIBILD\t\u00ae\t, TRUVADA\t\u00ae\t, TRUVADA FOR PREP\t\u00ae\t, TYBOST\t\u00ae\t, VEMLIDY\t\u00ae\t, VIREAD\t\u00ae\t, VOSEVI\t\u00ae\t, YESCARTA\t\u00ae\tand ZYDELIG\t\u00ae\t. LEXISCAN\t\u00ae\tis a registered trademark of Astellas U.S. LLC. MACUGEN\t\u00ae\tis a registered trademark of Eyetech, Inc. SYMTUZA\t\u00ae\tis a registered trademark of Janssen Sciences Ireland UC. TAMIFLU\t\u00ae\tis a registered trademark of Hoffmann-La Roche Inc. This report also includes other trademarks, service marks and trade names of other companies.\tPART I.\tFINANCIAL INFORMATION\tItem 1.    CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED BALANCE SHEETS\t(unaudited)\t(in millions, except per share amounts)\tMarch 31, 2020\tDecember 31, 2019\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t10,051\t$\t11,631\tShort-term marketable securities\t10,734\t12,721\tAccounts receivable, net of allowances of $793 and $758, respectively\t3,907\t3,582\tInventories\t986\t922\tPrepaid and other current assets\t1,272\t1,440\tTotal current assets\t26,950\t30,296\tProperty, plant and equipment, net\t4,564\t4,502\tLong-term marketable securities\t3,529\t1,488\tIntangible assets, net\t13,502\t13,786\tGoodwill\t4,117\t4,117\tOther long-term assets\t7,079\t7,438\tTotal assets\t$\t59,741\t$\t61,627\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t590\t$\t713\tAccrued government and other rebates\t3,457\t3,473\tOther accrued liabilities\t2,833\t3,074\tCurrent portion of long-term debt and other obligations, net\t1,999\t2,499\tTotal current liabilities\t8,879\t9,759\tLong-term debt, net\t22,098\t22,094\tLong",
            "CONSOLIDATED BALANCE SHEETS\t(unaudited)\t(in millions, except per share amounts)\tMarch 31, 2020\tDecember 31, 2019\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t10,051\t$\t11,631\tShort-term marketable securities\t10,734\t12,721\tAccounts receivable, net of allowances of $793 and $758, respectively\t3,907\t3,582\tInventories\t986\t922\tPrepaid and other current assets\t1,272\t1,440\tTotal current assets\t26,950\t30,296\tProperty, plant and equipment, net\t4,564\t4,502\tLong-term marketable securities\t3,529\t1,488\tIntangible assets, net\t13,502\t13,786\tGoodwill\t4,117\t4,117\tOther long-term assets\t7,079\t7,438\tTotal assets\t$\t59,741\t$\t61,627\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t590\t$\t713\tAccrued government and other rebates\t3,457\t3,473\tOther accrued liabilities\t2,833\t3,074\tCurrent portion of long-term debt and other obligations, net\t1,999\t2,499\tTotal current liabilities\t8,879\t9,759\tLong-term debt, net\t22,098\t22,094\tLong-term income taxes payable\t5,595\t6,115\tOther long-term obligations\t990\t1,009\tCommitments and contingencies (Note 10)\tStockholders  equity:\tPreferred stock, par value $0.001 per share; 5 shares authorized; none outstanding\t \t \tCommon stock, par value $0.001 per share; 5,600 shares authorized; 1,254 and 1,266 shares issued and outstanding, respectively\t1\t1\tAdditional paid-in capital\t3,311\t3,051\tAccumulated other comprehensive income\t46\t85\tRetained earnings\t18,709\t19,388\tTotal Gilead stockholders  equity\t22,067\t22,525\tNoncontrolling interest\t112\t125\tTotal stockholders  equity\t22,179\t22,650\tTotal liabilities and stockholders  equity\t$\t59,741\t$\t61,627\tSee accompanying notes.\t2\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS OF INCOME\t(unaudited)\t(in millions, except per share amounts)\tThree Months Ended\tMarch 31,\t2020\t2019\tRevenues:\tProduct sales\t$\t5,467\t$\t5,200\tRoyalty, contract and other revenues\t81\t81\tTotal revenues\t5,548\t5,281\tCosts and expenses:\tCost of goods sold\t969\t957\tResearch and development expenses\t1,101\t1,057\tSelling, general and administrative expenses\t1,076\t1,030\tTotal costs and expenses\t3,146\t3,044\tIncome from operations\t2,402\t2,237\tInterest expense\t(\t241\t)\t(\t254\t)\tOther income (expense), net\t(\t158\t)\t367\tIncome before provision for income taxes\t2,003\t2,350\tProvision for income taxes\t465\t382\tNet income\t1,538\t1,968\tNet loss attributable to noncontrolling interest\t(\t13\t)\t(\t7\t)\tNet income attributable to Gilead\t$\t1,551\t$\t1,975\tNet income per share attributable to Gilead common stockholders - basic\t$\t1.23\t$\t1.55\tShares used in per share calculation - basic\t1,262\t1,276\tNet income per share attributable to Gilead common stockholders - diluted\t$\t1.22\t$\t1.54\tShares used in per share calculation - diluted\t1,270\t1,283\tSee accompanying notes.\t3\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME\t(unaudited)\t(in millions)\tThree Months Ended\tMarch 31,\t2020\t2019\tNet income\t$\t1,538\t$\t1,968\tOther comprehensive income:\tNet foreign currency translation (loss) gain, net of tax\t(\t39\t)\t21\tAvai",
            "Consolidated Balance Sheets\t. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs in our\tCondensed Consolidated Balance Sheets\t. The remaining financial instruments are reported in our\tCondensed Consolidated Balance Sheets\tat amounts that approximate current fair values.\t10\tThe following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):\tMarch 31, 2020\tDecember 31, 2019\tLevel 1\tLevel 2\tLevel 3\tTotal\tLevel 1\tLevel 2\tLevel 3\tTotal\tAssets:\tAvailable-for-sale debt securities:\tU.S. treasury securities\t$\t2,072\t$\t \t$\t \t$\t2,072\t$\t2,433\t$\t \t$\t \t$\t2,433\tCertificates of deposit\t \t3,201\t \t3,201\t \t3,517\t \t3,517\tU.S. government agencies securities\t \t134\t \t134\t \t1,081\t \t1,081\tNon-U.S. government securities\t \t22\t \t22\t \t174\t \t174\tCorporate debt securities\t \t9,235\t \t9,235\t \t9,204\t \t9,204\tResidential mortgage and asset-backed securities\t \t256\t \t256\t \t91\t \t91\tEquity securities:\tEquity investment in Galapagos\t3,316\t \t \t3,316\t3,477\t \t \t3,477\tMoney market funds\t7,763\t \t \t7,763\t7,069\t \t \t7,069\tOther publicly traded equity securities\t239\t \t \t239\t322\t \t \t322\tDeferred compensation plan\t156\t \t \t156\t171\t \t \t171\tForeign currency derivative contracts\t \t76\t \t76\t \t37\t \t37\tTotal\t$\t13,546\t$\t12,924\t$\t \t$\t26,470\t$\t13,472\t$\t14,104\t$\t \t$\t27,576\tLiabilities:\tDeferred compensation plan\t$\t156\t$\t \t$\t \t$\t156\t$\t171\t$\t \t$\t \t$\t171\tForeign currency derivative contracts\t \t5\t \t5\t \t8\t \t8\tTotal\t$\t156\t$\t5\t$\t \t$\t161\t$\t171\t$\t8\t$\t \t$\t179\tChanges in the fair value of equity securities resulted in a net unrealized loss of\t$\t283\tmillion\tand a net unrealized gain of\t$\t197\tmillion\tfor the\tthree months ended March 31, 2020\tand\t2019\t, respectively, which were included in\tOther income (expense), net\ton our\tCondensed Consolidated Statements of Income\t.\tOur equity investment in Galapagos NV (Galapagos) is classified as Other long-term assets on our\tCondensed Consolidated Balance Sheets\t.\tThe following table summarizes the classification of our equity securities in our\tCondensed Consolidated Balance Sheets\t(in millions):\tMarch 31, 2020\tDecember 31, 2019\tCash and cash equivalents\t$\t7,763\t$\t7,069\tPrepaid and other current assets\t239\t319\tOther long-term assets\t3,472\t3,651\tTotal\t$\t11,474\t$\t11,039\tOur available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our\tCondensed Consolidated Balance Sheets\t. See Note\t4. Available-For-Sale Debt Securities\tfor additional information.\tLevel 2 Inputs\tWe estimate the fair values of Level 2 instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry stand",
            "Consolidated Balance Sheets\t. The remaining financial instruments are reported in our\tCondensed Consolidated Balance Sheets\tat amounts that approximate current fair values.\t10\tThe following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):\tMarch 31, 2020\tDecember 31, 2019\tLevel 1\tLevel 2\tLevel 3\tTotal\tLevel 1\tLevel 2\tLevel 3\tTotal\tAssets:\tAvailable-for-sale debt securities:\tU.S. treasury securities\t$\t2,072\t$\t \t$\t \t$\t2,072\t$\t2,433\t$\t \t$\t \t$\t2,433\tCertificates of deposit\t \t3,201\t \t3,201\t \t3,517\t \t3,517\tU.S. government agencies securities\t \t134\t \t134\t \t1,081\t \t1,081\tNon-U.S. government securities\t \t22\t \t22\t \t174\t \t174\tCorporate debt securities\t \t9,235\t \t9,235\t \t9,204\t \t9,204\tResidential mortgage and asset-backed securities\t \t256\t \t256\t \t91\t \t91\tEquity securities:\tEquity investment in Galapagos\t3,316\t \t \t3,316\t3,477\t \t \t3,477\tMoney market funds\t7,763\t \t \t7,763\t7,069\t \t \t7,069\tOther publicly traded equity securities\t239\t \t \t239\t322\t \t \t322\tDeferred compensation plan\t156\t \t \t156\t171\t \t \t171\tForeign currency derivative contracts\t \t76\t \t76\t \t37\t \t37\tTotal\t$\t13,546\t$\t12,924\t$\t \t$\t26,470\t$\t13,472\t$\t14,104\t$\t \t$\t27,576\tLiabilities:\tDeferred compensation plan\t$\t156\t$\t \t$\t \t$\t156\t$\t171\t$\t \t$\t \t$\t171\tForeign currency derivative contracts\t \t5\t \t5\t \t8\t \t8\tTotal\t$\t156\t$\t5\t$\t \t$\t161\t$\t171\t$\t8\t$\t \t$\t179\tChanges in the fair value of equity securities resulted in a net unrealized loss of\t$\t283\tmillion\tand a net unrealized gain of\t$\t197\tmillion\tfor the\tthree months ended March 31, 2020\tand\t2019\t, respectively, which were included in\tOther income (expense), net\ton our\tCondensed Consolidated Statements of Income\t.\tOur equity investment in Galapagos NV (Galapagos) is classified as Other long-term assets on our\tCondensed Consolidated Balance Sheets\t.\tThe following table summarizes the classification of our equity securities in our\tCondensed Consolidated Balance Sheets\t(in millions):\tMarch 31, 2020\tDecember 31, 2019\tCash and cash equivalents\t$\t7,763\t$\t7,069\tPrepaid and other current assets\t239\t319\tOther long-term assets\t3,472\t3,651\tTotal\t$\t11,474\t$\t11,039\tOur available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our\tCondensed Consolidated Balance Sheets\t. See Note\t4. Available-For-Sale Debt Securities\tfor additional information.\tLevel 2 Inputs\tWe estimate the fair values of Level 2 instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on h",
            "Consolidated Balance Sheets\tat amounts that approximate current fair values.\t10\tThe following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):\tMarch 31, 2020\tDecember 31, 2019\tLevel 1\tLevel 2\tLevel 3\tTotal\tLevel 1\tLevel 2\tLevel 3\tTotal\tAssets:\tAvailable-for-sale debt securities:\tU.S. treasury securities\t$\t2,072\t$\t \t$\t \t$\t2,072\t$\t2,433\t$\t \t$\t \t$\t2,433\tCertificates of deposit\t \t3,201\t \t3,201\t \t3,517\t \t3,517\tU.S. government agencies securities\t \t134\t \t134\t \t1,081\t \t1,081\tNon-U.S. government securities\t \t22\t \t22\t \t174\t \t174\tCorporate debt securities\t \t9,235\t \t9,235\t \t9,204\t \t9,204\tResidential mortgage and asset-backed securities\t \t256\t \t256\t \t91\t \t91\tEquity securities:\tEquity investment in Galapagos\t3,316\t \t \t3,316\t3,477\t \t \t3,477\tMoney market funds\t7,763\t \t \t7,763\t7,069\t \t \t7,069\tOther publicly traded equity securities\t239\t \t \t239\t322\t \t \t322\tDeferred compensation plan\t156\t \t \t156\t171\t \t \t171\tForeign currency derivative contracts\t \t76\t \t76\t \t37\t \t37\tTotal\t$\t13,546\t$\t12,924\t$\t \t$\t26,470\t$\t13,472\t$\t14,104\t$\t \t$\t27,576\tLiabilities:\tDeferred compensation plan\t$\t156\t$\t \t$\t \t$\t156\t$\t171\t$\t \t$\t \t$\t171\tForeign currency derivative contracts\t \t5\t \t5\t \t8\t \t8\tTotal\t$\t156\t$\t5\t$\t \t$\t161\t$\t171\t$\t8\t$\t \t$\t179\tChanges in the fair value of equity securities resulted in a net unrealized loss of\t$\t283\tmillion\tand a net unrealized gain of\t$\t197\tmillion\tfor the\tthree months ended March 31, 2020\tand\t2019\t, respectively, which were included in\tOther income (expense), net\ton our\tCondensed Consolidated Statements of Income\t.\tOur equity investment in Galapagos NV (Galapagos) is classified as Other long-term assets on our\tCondensed Consolidated Balance Sheets\t.\tThe following table summarizes the classification of our equity securities in our\tCondensed Consolidated Balance Sheets\t(in millions):\tMarch 31, 2020\tDecember 31, 2019\tCash and cash equivalents\t$\t7,763\t$\t7,069\tPrepaid and other current assets\t239\t319\tOther long-term assets\t3,472\t3,651\tTotal\t$\t11,474\t$\t11,039\tOur available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our\tCondensed Consolidated Balance Sheets\t. See Note\t4. Available-For-Sale Debt Securities\tfor additional information.\tLevel 2 Inputs\tWe estimate the fair values of Level 2 instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.\tSubstantially all of our foreign currency derivative",
            "Consolidated Balance Sheets\t(in millions):\tMarch 31, 2020\tDecember 31, 2019\tCash and cash equivalents\t$\t657\t$\t2,291\tShort-term marketable securities\t10,734\t12,721\tLong-term marketable securities\t3,529\t1,488\tTotal\t$\t14,920\t$\t16,500\tAccrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities was\t$\t60\tmillion\tand\t$\t37\tmillion\tas of\tMarch 31, 2020\tand\tDecember 31, 2019\t, respectively, and is recorded in Prepaid and other current assets on our\tCondensed Consolidated Balance Sheets\t. In connection with the adoption of the new credit loss standard, we made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. There were\tno\twrite-offs of accrued interest receivable during the three months ended\tMarch 31, 2020\t.\tThe following table summarizes our available-for-sale debt securities by contractual maturity (in millions):\tMarch 31, 2020\tAmortized Cost\tFair Value\tWithin one year\t$\t11,420\t$\t11,391\tAfter one year through five years\t3,513\t3,510\tAfter five years\t19\t19\tTotal\t$\t14,952\t$\t14,920\t12\tThe following table summarizes our available-for-sale debt securities in an unrealized loss position (in millions):\tLess Than 12 Months\t12 Months or Greater\tTotal\tGross\tUnrealized\tLosses\tEstimated\tFair Value\tGross\tUnrealized\tLosses\tEstimated\tFair Value\tGross\tUnrealized\tLosses\tEstimated\tFair Value\tMarch 31, 2020\tCorporate debt securities\t$\t(\t55\t)\t$\t5,639\t$\t \t$\t \t$\t(\t55\t)\t$\t5,639\tResidential mortgage and asset-backed securities\t(\t4\t)\t229\t \t6\t(\t4\t)\t235\tTotal\t$\t(\t59\t)\t$\t5,868\t$\t \t$\t6\t$\t(\t59\t)\t$\t5,874\tDecember 31, 2019\tCorporate debt securities\t$\t(\t1\t)\t$\t1,866\t$\t \t$\t4\t$\t(\t1\t)\t$\t1,870\tWe held a total of\t873\tpositions which were in an unrealized loss position as of\tMarch 31, 2020\t. The unrealized losses are largely due to changes in interest rates. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly,\tno\tcredit losses were recognized for the\tthree months ended March 31, 2020\t.\t5\t.\tDERIVATIVE FINANCIAL INSTRUMENTS\tOur operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contract",
            "Consolidated Balance Sheets\t(in millions):\tMarch 31, 2020\tAsset Derivatives\tLiability Derivatives\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tOther current assets\t$\t68\tOther accrued liabilities\t$\t(\t4\t)\tForeign currency exchange contracts\tOther long-term assets\t7\tOther long-term obligations\t(\t1\t)\tTotal derivatives designated as hedges\t75\t(\t5\t)\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tOther current assets\t1\tOther accrued liabilities\t \tTotal derivatives not designated as hedges\t1\t \tTotal derivatives\t$\t76\t$\t(\t5\t)\tDecember 31, 2019\tAsset Derivatives\tLiability Derivatives\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tOther current assets\t$\t36\tOther accrued liabilities\t$\t(\t6\t)\tForeign currency exchange contracts\tOther long-term assets\t \tOther long-term obligations\t(\t2\t)\tTotal derivatives designated as hedges\t36\t(\t8\t)\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tOther current assets\t1\tOther accrued liabilities\t \tTotal derivatives not designated as hedges\t1\t \tTotal derivatives\t$\t37\t$\t(\t8\t)\tThe following table summarizes the effect of our foreign currency exchange contracts on our\tCondensed Consolidated Financial Statements\t(in millions):\tThree Months Ended\tMarch 31,\t2020\t2019\tDerivatives designated as hedges:\tGains recognized in AOCI\t$\t66\t$\t28\tGains reclassified from AOCI into product sales\t27\t29\tDerivatives not designated as hedges:\tGains (losses) recognized in Other income (expense), net\t$\t24\t$\t(\t6\t)\tFrom time to time, we may discontinue cash flow hedges and, as a result, record related amounts in\tOther income (expense), net\ton our\tCondensed Consolidated Statements of Income\t. There was\tno\tdiscontinuance of cash flow hedges for the\tthree months ended March 31, 2020\tand\t2019\t.\t14\tAs of\tMarch 31, 2020\tand\tDecember 31, 2019\t, we only held foreign currency exchange contracts.\tThe following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our\tCondensed Consolidated Balance Sheets\t(in millions):\tGross Amounts Not Offset\ton our Condensed\tConsolidated Balance Sheets\tDescription\tGross Amounts\tof Recognized\tAssets/Liabilities\tGross Amounts\tOffset on our\tCondensed\tConsolidated\tBalance Sheets\tAmounts of Assets/Liabilities Presented\ton our Condensed Consolidated\tBalance Sheets\tDerivative\tFinancial\tInstruments\tCash Collateral\tReceived/\tPledged\tNet Amount\t(Legal Offset)\tAs of March 31, 2020\tDerivative assets\t$\t76\t$\t \t$\t76\t$\t(\t5\t)\t$\t \t$\t71\tDerivative liabilities\t(\t5\t)\t \t(\t5\t)\t5\t \t \tAs of December 31, 2019\tDerivative assets\t$\t37\t$\t \t$\t37\t$\t(\t6\t)\t$\t \t$\t31\tDerivative liabilities\t(\t8\t)\t \t(\t8\t)\t7\t \t(\t1\t)\t6\t.\tACQUISITION, COLLABORATIONS AND OTHER ARRANGEMENTS\tWe continue to pursue acquisitions, in licensing and strategic collaborations and other similar arrangements with third parties for the development and commercia",
            "Consolidated Balance Sheets\t(in millions):\tGross Amounts Not Offset\ton our Condensed\tConsolidated Balance Sheets\tDescription\tGross Amounts\tof Recognized\tAssets/Liabilities\tGross Amounts\tOffset on our\tCondensed\tConsolidated\tBalance Sheets\tAmounts of Assets/Liabilities Presented\ton our Condensed Consolidated\tBalance Sheets\tDerivative\tFinancial\tInstruments\tCash Collateral\tReceived/\tPledged\tNet Amount\t(Legal Offset)\tAs of March 31, 2020\tDerivative assets\t$\t76\t$\t \t$\t76\t$\t(\t5\t)\t$\t \t$\t71\tDerivative liabilities\t(\t5\t)\t \t(\t5\t)\t5\t \t \tAs of December 31, 2019\tDerivative assets\t$\t37\t$\t \t$\t37\t$\t(\t6\t)\t$\t \t$\t31\tDerivative liabilities\t(\t8\t)\t \t(\t8\t)\t7\t \t(\t1\t)\t6\t.\tACQUISITION, COLLABORATIONS AND OTHER ARRANGEMENTS\tWe continue to pursue acquisitions, in licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may include non-refundable up-front payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit sharing arrangements, cost sharing arrangements and equity investments.\tAcquisition\tForty Seven\tOn April 7, 2020, we acquired all of the outstanding common stock of Forty Seven, Inc. (Forty Seven), a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of\t$\t95.50\tper share in cash, or approximately\t$\t4.9\tbillion\t. As a result, Forty Seven became our wholly-owned subsidiary. Forty Seven s lead program, magrolimab, is a monoclonal antibody in clinical development for the treatment of myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors.\tThis transaction will be accounted for as an asset acquisition because the lead asset, magrolimab, represents substantially all the fair value of the assets acquired. As such, substantially all of the purchase price will be expensed as acquired in-process research and development (IPR&D) within\tResearch and development expenses\ton our\tCondensed Consolidated Statements of Income\tduring the three months ended June 30, 2020.\tCollaborations and Other Arrangements\tDuring the\tthree months ended March 31, 2020\tand\t2019\t, we entered into several collaborative and other similar arrangements, including equity investments and licensing arrangements, that we do not consider to be individually material. Cash outflows and accrued expenses for up-front payments related to these arrangements totaled\t$\t105\tmillion\tand\t$\t187\tmillion\tfor the\tthree months ended March 31, 2020\tand\t2019\t, respectively, of which\t$\t97\tmillion\tand\t$\t126\tmillion\t, respectively, were recorded as up-front collaboration and licensing expenses within\tResearch and development expenses\ton our\tCondensed Consolidated St",
            "Consolidated Balance Sheets\tDescription\tGross Amounts\tof Recognized\tAssets/Liabilities\tGross Amounts\tOffset on our\tCondensed\tConsolidated\tBalance Sheets\tAmounts of Assets/Liabilities Presented\ton our Condensed Consolidated\tBalance Sheets\tDerivative\tFinancial\tInstruments\tCash Collateral\tReceived/\tPledged\tNet Amount\t(Legal Offset)\tAs of March 31, 2020\tDerivative assets\t$\t76\t$\t \t$\t76\t$\t(\t5\t)\t$\t \t$\t71\tDerivative liabilities\t(\t5\t)\t \t(\t5\t)\t5\t \t \tAs of December 31, 2019\tDerivative assets\t$\t37\t$\t \t$\t37\t$\t(\t6\t)\t$\t \t$\t31\tDerivative liabilities\t(\t8\t)\t \t(\t8\t)\t7\t \t(\t1\t)\t6\t.\tACQUISITION, COLLABORATIONS AND OTHER ARRANGEMENTS\tWe continue to pursue acquisitions, in licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may include non-refundable up-front payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit sharing arrangements, cost sharing arrangements and equity investments.\tAcquisition\tForty Seven\tOn April 7, 2020, we acquired all of the outstanding common stock of Forty Seven, Inc. (Forty Seven), a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of\t$\t95.50\tper share in cash, or approximately\t$\t4.9\tbillion\t. As a result, Forty Seven became our wholly-owned subsidiary. Forty Seven s lead program, magrolimab, is a monoclonal antibody in clinical development for the treatment of myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors.\tThis transaction will be accounted for as an asset acquisition because the lead asset, magrolimab, represents substantially all the fair value of the assets acquired. As such, substantially all of the purchase price will be expensed as acquired in-process research and development (IPR&D) within\tResearch and development expenses\ton our\tCondensed Consolidated Statements of Income\tduring the three months ended June 30, 2020.\tCollaborations and Other Arrangements\tDuring the\tthree months ended March 31, 2020\tand\t2019\t, we entered into several collaborative and other similar arrangements, including equity investments and licensing arrangements, that we do not consider to be individually material. Cash outflows and accrued expenses for up-front payments related to these arrangements totaled\t$\t105\tmillion\tand\t$\t187\tmillion\tfor the\tthree months ended March 31, 2020\tand\t2019\t, respectively, of which\t$\t97\tmillion\tand\t$\t126\tmillion\t, respectively, were recorded as up-front collaboration and licensing expenses within\tResearch and development expenses\ton our\tCondensed Consolidated Statements of Income\t.\tUnder the financial terms of these arrangements, we may be requi"
        ],
        "timestamp": "2025-01-21_09-38-21"
    }
}